In humans, IL-18, one of the downstream signaling events of the NLRP3 inflammasome, is elevated in patients with osteoporosis [60], and therapeutics targeting the NLRP3 inflammasome are of interest for osteoporosis treatment [61]. This evidence concerns the gene NLRP3 and osteoporosis.